Prognostic Significance of miR-181b and miR-21 in Gastric Cancer Patients
Author Information
Author(s): Jiang Jingting, Zheng Xiao, Xu Xiao, Zhou Qi, Yan Haijiao, Zhang Xueguang, Lu Binfeng, Wu Changping, Ju Jingfang
Primary Institution: The Third Affiliated Hospital of Soochow University
Hypothesis
The study aims to evaluate the effectiveness of S-1/Oxaliplatin vs. Doxifluridine/Oxaliplatin and identify miRNAs as potential prognostic biomarkers in gastric cancer patients.
Conclusion
Patients treated with S-1/Oxaliplatin had a better response than those treated with Doxifluridine/Oxaliplatin, and miR-21 and miR-181b are potential prognostic biomarkers in late stage gastric cancer.
Supporting Evidence
- The overall response rate for S-1/Oxaliplatin was 33.3% compared to 17.6% for Doxifluridine/Oxaliplatin.
- Average overall survival was 7.80 months for S-1/Oxaliplatin and 7.30 months for Doxifluridine/Oxaliplatin.
- Low levels of miR-21 and miR-181b were associated with better overall survival.
Takeaway
This study found that a specific treatment for stomach cancer works better than another, and two tiny molecules in the body could help doctors predict how well patients will do.
Methodology
The expression of candidate miRNAs was quantified from FFPE specimens using real-time qRT-PCR analysis.
Limitations
The study is limited to late stage gastric cancer patients and may not be generalizable to earlier stages.
Participant Demographics
Patients with late stage gastric cancer, KPS>70.
Statistical Information
P-Value
P=0.0004 for miR-21; P=0.018 for miR-181b
Confidence Interval
CI=0.06–0.45 for miR-21; CI=0.16–0.87 for miR-181b
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website